A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

NCT03677141 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: Mosunetuzumab
DRUG: Polatuzumab Vedotin
DRUG: Rituxumab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Tocilizumab

Sponsor

Hoffmann-La Roche